Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
2.88
Dollar change
0.00
Percentage change
0.00
%
Index- P/E- EPS (ttm)-1.59 Insider Own39.80% Shs Outstand65.47M Perf Week3.60%
Market Cap188.55M Forward P/E- EPS next Y-0.61 Insider Trans-0.10% Shs Float39.41M Perf Month93.29%
Income-30.04M PEG- EPS next Q-0.22 Inst Own23.55% Short Float13.02% Perf Quarter119.85%
Sales0.00M P/S- EPS this Y67.88% Inst Trans6.47% Short Ratio1.70 Perf Half Y111.76%
Book/sh1.05 P/B2.75 EPS next Y-20.20% ROA-77.55% Short Interest5.13M Perf Year246.78%
Cash/sh0.36 P/C7.91 EPS next 5Y39.60% ROE-110.27% 52W Range0.77 - 3.79 Perf YTD125.00%
Dividend Est.- P/FCF- EPS past 5Y50.96% ROI-135.05% 52W High-24.01% Beta1.55
Dividend TTM- Quick Ratio2.96 Sales past 5Y1867.07% Gross Margin- 52W Low274.03% ATR (14)0.31
Dividend Ex-Date- Current Ratio2.96 EPS Y/Y TTM14.84% Oper. Margin0.00% RSI (14)75.92 Volatility9.96% 16.39%
Employees30 Debt/Eq0.15 Sales Y/Y TTM- Profit Margin- Recom1.50 Target Price7.25
Option/ShortYes / Yes LT Debt/Eq0.05 EPS Q/Q1.21% Payout- Rel Volume0.27 Prev Close2.88
Sales Surprise- EPS Surprise-0.08% Sales Q/Q- EarningsMar 21 AMC Avg Volume3.02M Price2.88
SMA2036.43% SMA5072.27% SMA20097.67% Trades Volume808,613 Change0.00%
Date Action Analyst Rating Change Price Target Change
Mar-18-24Initiated Leerink Partners Outperform $6
Mar-28-18Initiated B. Riley FBR, Inc. Neutral $1
Jan-05-18Initiated Leerink Partners Outperform $2
Jun-13-17Reiterated Chardan Capital Markets Buy $5 → $2.50
Mar-06-17Reiterated Wedbush Outperform $8 → $6
Jan-30-17Downgrade Wells Fargo Outperform → Market Perform
Jan-30-17Downgrade Needham Buy → Hold
Dec-07-16Reiterated Chardan Capital Markets Buy $12 → $5
Nov-02-16Reiterated Needham Buy $10 → $9
Jul-25-16Reiterated Chardan Capital Markets Buy $14.50 → $12
Mar-23-24 05:33AM
Mar-21-24 10:53PM
04:22PM
04:05PM
Mar-13-24 12:09PM
06:32AM Loading…
Mar-12-24 06:32AM
06:30AM
Jan-02-24 04:05PM
Nov-22-23 08:00AM
Nov-09-23 04:32PM
04:05PM
Nov-02-23 08:00AM
Oct-19-23 08:00AM
Sep-20-23 07:00AM
Sep-13-23 08:00AM
08:00AM Loading…
Sep-05-23 08:00AM
Aug-24-23 07:33PM
Aug-23-23 01:04PM
08:00AM
Aug-08-23 04:43PM
04:05PM
Aug-02-23 08:00AM
Jul-18-23 08:00AM
Jun-27-23 08:00AM
Jun-23-23 08:00AM
Jun-20-23 08:00AM
Jun-12-23 08:00AM
May-16-23 08:00AM
May-11-23 04:18PM
04:05PM
08:00AM Loading…
Apr-13-23 08:00AM
Apr-12-23 04:05PM
Mar-23-23 04:52PM
04:05PM
Feb-09-23 08:00AM
Jan-13-23 04:05PM
Jan-09-23 06:01AM
Dec-12-22 08:00AM
Nov-29-22 05:43PM
08:00AM
Nov-10-22 04:05PM
Nov-03-22 08:00AM
Nov-02-22 08:00AM
Sep-13-22 11:58AM
Sep-12-22 11:14AM
08:00AM
Sep-02-22 04:05PM
Aug-11-22 04:10PM
Aug-04-22 08:00AM
Jun-21-22 08:00AM
Jun-13-22 08:00AM
Jun-02-22 08:00AM
May-17-22 04:30PM
07:00AM
May-12-22 04:05PM
10:20AM
May-11-22 08:00AM
May-05-22 04:05PM
Mar-24-22 12:03PM
08:00AM
Mar-10-22 04:05PM
Mar-03-22 05:15PM
Feb-24-22 08:00AM
Feb-10-22 04:30PM
Jan-26-22 10:00AM
Jan-20-22 05:18PM
Jan-19-22 09:38AM
Jan-04-22 08:00AM
Dec-03-21 08:30AM
Dec-01-21 08:30AM
Nov-30-21 05:23PM
Nov-24-21 04:05PM
Nov-10-21 05:45PM
04:05PM
Nov-03-21 05:15PM
Oct-28-21 03:05PM
Oct-13-21 03:11PM
12:27PM
07:27AM
Oct-12-21 04:05PM
Sep-30-21 04:45PM
Sep-09-21 04:40PM
Sep-06-21 02:33PM
Aug-10-21 05:55PM
04:05PM
Aug-03-21 05:15PM
Jun-30-21 09:33AM
Jun-25-21 01:38PM
07:05AM
Jun-21-21 07:00AM
Jun-11-21 08:56AM
May-21-21 10:47AM
08:07AM
May-14-21 04:07PM
May-13-21 05:35PM
04:07PM
03:15PM
May-06-21 03:01PM
May-03-21 09:25AM
08:00AM
Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded on September 5, 2007 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hagan Joseph PChief Executive OfficerJan 18 '24Sale1.1914,58017,35957,112Jan 18 08:22 PM
CALSADA CRISPINAChief Financial OfficerJan 18 '24Sale1.195,4686,5105,782Jan 18 08:24 PM
Aker Christopher RaySr. VP & General CounselJan 18 '24Sale1.195,4686,51010,056Jan 18 08:23 PM
Last Close
Mar 28 04:00PM ET
32.78
Dollar change
-0.34
Percentage change
-1.03
%
VSTO Vista Outdoor Inc daily Stock Chart
IndexRUT P/E- EPS (ttm)-5.98 Insider Own13.59% Shs Outstand57.09M Perf Week1.49%
Market Cap1.91B Forward P/E7.22 EPS next Y4.54 Insider Trans0.02% Shs Float50.24M Perf Month6.43%
Income-340.01M PEG- EPS next Q0.91 Inst Own85.05% Short Float3.22% Perf Quarter9.82%
Sales2.79B P/S0.68 EPS this Y-40.47% Inst Trans-1.47% Short Ratio3.21 Perf Half Y-0.15%
Book/sh18.63 P/B1.76 EPS next Y19.09% ROA-11.76% Short Interest1.62M Perf Year24.50%
Cash/sh0.98 P/C33.42 EPS next 5Y3.05% ROE-27.16% 52W Range23.33 - 33.96 Perf YTD10.86%
Dividend Est.- P/FCF4.94 EPS past 5Y32.03% ROI-17.51% 52W High-3.47% Beta0.96
Dividend TTM- Quick Ratio1.09 Sales past 5Y7.84% Gross Margin31.32% 52W Low40.51% ATR (14)0.75
Dividend Ex-Date- Current Ratio2.58 EPS Y/Y TTM-184.62% Oper. Margin9.44% RSI (14)59.95 Volatility2.68% 2.40%
Employees7000 Debt/Eq0.87 Sales Y/Y TTM-11.26% Profit Margin-12.17% Recom1.50 Target Price34.00
Option/ShortYes / Yes LT Debt/Eq0.79 EPS Q/Q-326.55% Payout- Rel Volume1.02 Prev Close33.12
Sales Surprise-0.86% EPS Surprise-1.48% Sales Q/Q-9.61% EarningsJan 31 AMC Avg Volume503.34K Price32.78
SMA201.84% SMA506.98% SMA20013.10% Trades Volume513,592 Change-1.03%
Date Action Analyst Rating Change Price Target Change
Feb-02-24Reiterated Monness Crespi & Hardt Buy $34 → $37
Dec-15-23Resumed B. Riley Securities Buy $32
Sep-20-22Initiated Jefferies Hold $26
Jul-26-22Downgrade ROTH Capital Buy → Neutral $53 → $32
Jul-13-22Initiated MKM Partners Buy $54
Jul-13-22Downgrade KeyBanc Capital Markets Overweight → Sector Weight
May-27-21Reiterated Monness Crespi & Hardt Buy $42 → $51
May-07-21Reiterated Monness Crespi & Hardt Buy $38 → $42
Apr-19-21Reiterated B. Riley Securities Buy $41 → $49
Feb-05-21Reiterated Monness Crespi & Hardt Buy $33 → $38
Today 04:37PM
02:52PM
Mar-26-24 12:25PM
Mar-25-24 05:06PM
12:53PM
08:52AM Loading…
08:52AM
08:22AM
08:15AM
07:00AM
Mar-22-24 09:54PM
09:26AM
Mar-18-24 04:01PM
Mar-16-24 04:54PM
Mar-14-24 08:29AM
Mar-12-24 07:00AM
08:08PM Loading…
Mar-08-24 08:08PM
Mar-07-24 07:00AM
Mar-04-24 02:37PM
07:26AM
07:04AM
06:53AM
06:45AM
Mar-01-24 10:30AM
09:42AM
09:33AM
09:25AM
09:17AM
Feb-20-24 07:00AM
Feb-09-24 04:10PM
Feb-02-24 09:02AM
07:00AM Loading…
07:00AM
01:55AM
Feb-01-24 12:54PM
12:22PM
Jan-31-24 05:13PM
04:37PM
04:30PM
Jan-30-24 09:14AM
Jan-22-24 11:38AM
07:00AM
Jan-10-24 04:01PM
Dec-19-23 07:24AM
Dec-13-23 07:30AM
Dec-12-23 07:30AM
Nov-30-23 03:22AM
02:58AM
Nov-29-23 07:57PM
Nov-24-23 01:09PM
11:50AM
09:49AM
09:44AM
07:23AM
03:01AM
Nov-23-23 04:05PM
04:51AM
04:24AM
Nov-22-23 11:19PM
09:18PM
Nov-20-23 01:00PM
Nov-17-23 07:00AM
Nov-16-23 09:18AM
Nov-03-23 03:03PM
01:25AM
Nov-01-23 06:24PM
05:54PM
04:30PM
Oct-27-23 12:08PM
Oct-26-23 10:02AM
Oct-25-23 10:02AM
Oct-23-23 07:00AM
Oct-21-23 05:24PM
Oct-19-23 07:00AM
Oct-17-23 10:18AM
Oct-16-23 05:31PM
04:55PM
04:01PM
02:21PM
12:14PM
12:13PM
11:42AM
10:52AM
08:07AM
08:00AM
Oct-10-23 12:21PM
Oct-05-23 10:05AM
Sep-26-23 07:00AM
Sep-22-23 10:18AM
Sep-21-23 09:15AM
Sep-12-23 04:35AM
Sep-11-23 08:38AM
Sep-05-23 04:10PM
Aug-11-23 03:12PM
Aug-10-23 04:01PM
09:55AM
Jul-28-23 07:00AM
Jul-26-23 05:15PM
04:10PM
04:01PM
Jul-24-23 08:16AM
Jul-21-23 09:00AM
Vista Outdoor, Inc. engages in the design, manufacture, and marketing of consumer products in the outdoor sports and recreation markets. It operates through the following segments: Shooting Sports and Outdoor Products. The Shooting Sports segment consists of ammunition and hunting & shooting accessories product lines. The Outdoor Products segment includes sports protection, outdoor cooking, golf, and hydration product lines. The company was founded in 2014 and is headquartered in Anoka, MN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MCARTHUR GARY LCEO - InterimNov 21 '23Buy25.941,73545,00694,560Nov 24 03:59 PM
Robinson Michael DDirectorJun 07 '23Sale27.764,159115,45421,430Jun 09 11:02 AM
Crandell Bradford EChief Human Resources OfficerJun 01 '23Sale26.363,954104,22756,690Jun 02 04:04 PM
Vanderbrink Jason RPresident, AmmunitionMay 09 '23Sale28.1126,500744,91578,358May 11 01:48 PM
Keegan AndrewInterim CFOApr 23 '23Sale26.0686022,41231,451Apr 25 02:42 PM
Ehrich JeffreyGC & Corp Secretary - InterimApr 23 '23Sale26.0667517,59012,711Apr 25 02:42 PM